199 related articles for article (PubMed ID: 20058228)
1. Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson's disease patients: a [I-123]FP-CIT SPECT study.
Nobili F; Campus C; Arnaldi D; De Carli F; Cabassi G; Brugnolo A; Dessi B; Morbelli S; Sambuceti G; Abbruzzese G; Rodriguez G
Mov Disord; 2010 Jan; 25(1):35-43. PubMed ID: 20058228
[TBL] [Abstract][Full Text] [Related]
2. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
[TBL] [Abstract][Full Text] [Related]
3. Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson's disease.
Nobili F; Arnaldi D; Campus C; Ferrara M; De Carli F; Brugnolo A; Dessi B; Girtler N; Morbelli S; Abruzzese G; Sambuceti G; Rodriguez G
Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2209-18. PubMed ID: 21744112
[TBL] [Abstract][Full Text] [Related]
4. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.
Iranzo A; Valldeoriola F; Lomeña F; Molinuevo JL; Serradell M; Salamero M; Cot A; Ros D; Pavía J; Santamaria J; Tolosa E
Lancet Neurol; 2011 Sep; 10(9):797-805. PubMed ID: 21802993
[TBL] [Abstract][Full Text] [Related]
5. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease.
Siepel FJ; Brønnick KS; Booij J; Ravina BM; Lebedev AV; Pereira JB; Grüner R; Aarsland D
Mov Disord; 2014 Dec; 29(14):1802-8. PubMed ID: 25284687
[TBL] [Abstract][Full Text] [Related]
6. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease.
Spiegel J; Hellwig D; Samnick S; Jost W; Möllers MO; Fassbender K; Kirsch CM; Dillmann U
J Neural Transm (Vienna); 2007 Mar; 114(3):331-5. PubMed ID: 16715205
[TBL] [Abstract][Full Text] [Related]
7. Uneven age effects of [(18)F]FP-CIT binding in the striatum of Parkinson's disease.
Lee CS; Kim SJ; Oh SJ; Kim HO; Yun SC; Doudet D; Kim JS
Ann Nucl Med; 2014 Nov; 28(9):874-9. PubMed ID: 25008292
[TBL] [Abstract][Full Text] [Related]
8. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease.
Happe S; Baier PC; Helmschmied K; Meller J; Tatsch K; Paulus W
J Neurol; 2007 Aug; 254(8):1037-43. PubMed ID: 17351722
[TBL] [Abstract][Full Text] [Related]
9. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
10. Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study.
Pellecchia MT; Picillo M; Santangelo G; Longo K; Moccia M; Erro R; Amboni M; Vitale C; Vicidomini C; Salvatore M; Barone P; Pappatà S
Acta Neurol Scand; 2015 May; 131(5):275-81. PubMed ID: 25644029
[TBL] [Abstract][Full Text] [Related]
11. Extrastriatal
Nicastro N; Garibotto V; Burkhard PR
BMC Neurol; 2020 May; 20(1):192. PubMed ID: 32416724
[TBL] [Abstract][Full Text] [Related]
12. Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers.
Arnaldi D; De Carli F; Famà F; Brugnolo A; Girtler N; Picco A; Pardini M; Accardo J; Proietti L; Massa F; Bauckneht M; Morbelli S; Sambuceti G; Nobili F
Mov Disord; 2017 Dec; 32(12):1738-1747. PubMed ID: 29119593
[TBL] [Abstract][Full Text] [Related]
13. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Pirker W
Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
[TBL] [Abstract][Full Text] [Related]
14. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
[TBL] [Abstract][Full Text] [Related]
15. Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2).
Yousaf T; Pagano G; Niccolini F; Politis M
J Neurol; 2019 May; 266(5):1203-1210. PubMed ID: 30820739
[TBL] [Abstract][Full Text] [Related]
16. What predicts cognitive decline in de novo Parkinson's disease?
Arnaldi D; Campus C; Ferrara M; Famà F; Picco A; De Carli F; Accardo J; Brugnolo A; Sambuceti G; Morbelli S; Nobili F
Neurobiol Aging; 2012 Jun; 33(6):1127.e11-20. PubMed ID: 22226489
[TBL] [Abstract][Full Text] [Related]
17. Striatal dopamine transporters and cognitive function in Parkinson's disease.
Stögbauer J; Rosar F; Dillmann U; Faßbender K; Ezziddin S; Spiegel J
Acta Neurol Scand; 2020 Oct; 142(4):385-391. PubMed ID: 32914881
[TBL] [Abstract][Full Text] [Related]
18. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease.
Rektorova I; Srovnalova H; Kubikova R; Prasek J
Mov Disord; 2008 Aug; 23(11):1580-7. PubMed ID: 18618663
[TBL] [Abstract][Full Text] [Related]
19. Right putamen and age are the most discriminant features to diagnose Parkinson's disease by using
Cascianelli S; Tranfaglia C; Fravolini ML; Bianconi F; Minestrini M; Nuvoli S; Tambasco N; Dottorini ME; Palumbo B
Hell J Nucl Med; 2017; 20 Suppl():165. PubMed ID: 29324935
[TBL] [Abstract][Full Text] [Related]
20. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease.
Eshuis SA; Maguire RP; Leenders KL; Jonkman S; Jager PL
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):200-9. PubMed ID: 16228235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
